Document is current

Article History

Accepted: 17 December 2024

First Online: 11 February 2025

Declarations

:

: This study was developed by IQVIA Portugal and supported by MSD Portugal.

: Gabriela Sousa, Luís Costa, Margarida Brito and Sónia Oliveira received honoraria from MSD Portugal for participation in the expert panel. Bernardo Rodrigues, João Ferreira and Joana Silva are employees of MSD Portugal. Margarida Borges and Luís Silva Miguel are employees of IQVIA Portugal and were contracted by MSD Portugal to conduct this study. Sónia Oliveira has served as a consultant to Novartis, Pfizer, Eli Lilly Nederland, AstraZeneca, Daiichi Sankyo, Gilead, MSD and Seagen; has received research funding from Pfizer; and has received accommodation services from Novartis, Pfizer, Daiichi Sankyo, Astellas, Bristol-Myers Squibb, AstraZeneca and Gilead. Luís Costa has received grants/research support from Eli Lilly Nederland, MSD, Roche and Amgen; has received honoraria from Servier, AstraZeneca and MSD; and has participated in a sponsored speaker bureau of Novartis, Pfizer, Eli Lilly Nederland, MSD and AstraZeneca. None of the other authors have declared any conflicts of interest.

: Gabriela Sousa, Luís Costa, Margarida Brito and Sónia Oliveira participated in the expert panel, provided useful insights for this study and reviewed the final article. Bernardo Rodrigues, João Ferreira and Joana Silva were responsible for the article development and revision. Margarida Borges and Luís Silva Miguel were responsible for model development, expert panel moderation, data collection and analysis, and article development.

: All the data analysed were anonymous; therefore, the authors declare that no patient data appear in this article.

: All participants included in the EP provided their informed consent.

: All participants included in the EP provided their consent for publication.

: All data supporting the findings are available within the article and supplementary material.

: Not applicable.